Swarthmore Group Inc decreased Thermo Fisher Scientific Inc (TMO) stake by 19.83% reported in 2017Q3 SEC filing. Swarthmore Group Inc sold 10,250 shares as Thermo Fisher Scientific Inc (TMO)’s stock rose 8.13%. The Swarthmore Group Inc holds 41,450 shares with $7.84 million value, down from 51,700 last quarter. Thermo Fisher Scientific Inc now has $82.29 billion valuation. The stock decreased 1.62% or $3.37 during the last trading session, reaching $205.21. About 1.42M shares traded. Thermo Fisher Scientific Inc. (NYSE:TMO) has risen 15.57% since March 2, 2017 and is uptrending. It has underperformed by 1.13% the S&P500.
Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) had a decrease of 52.67% in short interest. DRNA’s SI was 335,400 shares in March as released by FINRA. Its down 52.67% from 708,700 shares previously. With 502,800 avg volume, 1 days are for Dicerna Pharmaceuticals Inc (NASDAQ:DRNA)’s short sellers to cover DRNA’s short positions. The SI to Dicerna Pharmaceuticals Inc’s float is 2.76%. The stock increased 0.16% or $0.02 during the last trading session, reaching $12.78. About 240,631 shares traded. Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) has declined 5.22% since March 2, 2017 and is downtrending. It has underperformed by 21.92% the S&P500.
Analysts await Thermo Fisher Scientific Inc. (NYSE:TMO) to report earnings on April, 25. They expect $2.40 EPS, up 15.38% or $0.32 from last year’s $2.08 per share. TMO’s profit will be $962.39M for 21.38 P/E if the $2.40 EPS becomes a reality. After $2.79 actual EPS reported by Thermo Fisher Scientific Inc. for the previous quarter, Wall Street now forecasts -13.98% negative EPS growth.
Since September 5, 2017, it had 0 insider buys, and 7 selling transactions for $20.40 million activity. CASPER MARC N sold $9.59M worth of stock. The insider Durbin Patrick M sold 6,000 shares worth $1.31M. HORNSTRA PETER E sold 3,894 shares worth $721,091. $7.32 million worth of Thermo Fisher Scientific Inc. (NYSE:TMO) was sold by Herrema Gregory J. on Friday, February 2. 1,000 shares valued at $211,430 were sold by Parrett William G on Friday, February 23. Williamson Stephen sold $1.05M worth of Thermo Fisher Scientific Inc. (NYSE:TMO) on Wednesday, February 7.
Among 19 analysts covering Thermo Fisher Scientific (NYSE:TMO), 18 have Buy rating, 0 Sell and 1 Hold. Therefore 95% are positive. Thermo Fisher Scientific had 61 analyst reports since July 24, 2015 according to SRatingsIntel. The stock of Thermo Fisher Scientific Inc. (NYSE:TMO) has “Buy” rating given on Tuesday, September 26 by Goldman Sachs. Leerink Swann reinitiated the stock with “Outperform” rating in Thursday, November 10 report. The rating was maintained by Jefferies on Tuesday, August 22 with “Hold”. The rating was downgraded by Cleveland to “Neutral” on Friday, September 9. The rating was maintained by Jefferies on Wednesday, September 27 with “Hold”. The firm earned “Hold” rating on Friday, October 20 by Jefferies. The firm earned “Buy” rating on Monday, September 25 by Barclays Capital. As per Tuesday, May 3, the company rating was maintained by Mizuho. Cowen & Co maintained Thermo Fisher Scientific Inc. (NYSE:TMO) rating on Friday, September 8. Cowen & Co has “Buy” rating and $220.0 target. The firm earned “Overweight” rating on Thursday, February 1 by Barclays Capital.
Investors sentiment increased to 0.96 in 2017 Q3. Its up 0.05, from 0.91 in 2017Q2. It is positive, as 51 investors sold TMO shares while 383 reduced holdings. 77 funds opened positions while 339 raised stakes. 333.20 million shares or 3.09% more from 323.23 million shares in 2017Q2 were reported. Teachers Retirement Of The State Of Kentucky holds 89,833 shares or 0.2% of its portfolio. 20,590 are held by Baxter Bros. Symphony Asset Mngmt Limited Liability Corporation reported 21,433 shares or 0.45% of all its holdings. San Francisco Sentry Group (Ca) owns 8,368 shares or 0.53% of their US portfolio. Comerica, Michigan-based fund reported 6,035 shares. Regions Corporation holds 0.41% or 192,625 shares. Parametric Port Limited Liability holds 910,403 shares. Birch Hill Inv Advsrs Ltd Company holds 4,255 shares. Us Comml Bank De stated it has 0.14% of its portfolio in Thermo Fisher Scientific Inc. (NYSE:TMO). Andra Ap reported 35,600 shares. Balasa Dinverno And Foltz Lc has invested 0.07% in Thermo Fisher Scientific Inc. (NYSE:TMO). Wilbanks Smith & Thomas Asset Management Ltd Liability holds 1,657 shares or 0.03% of its portfolio. 11,514 were accumulated by Whittier Tru. Wheatland Advisors has invested 0.84% of its portfolio in Thermo Fisher Scientific Inc. (NYSE:TMO). Cookson Peirce And Incorporated owns 0.36% invested in Thermo Fisher Scientific Inc. (NYSE:TMO) for 18,200 shares.
Among 7 analysts covering Dicerna Pharmaceuticals (NASDAQ:DRNA), 5 have Buy rating, 0 Sell and 2 Hold. Therefore 71% are positive. Dicerna Pharmaceuticals had 19 analyst reports since August 7, 2015 according to SRatingsIntel. The stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) earned “Mkt Perform” rating by Leerink Swann on Tuesday, January 31. As per Thursday, June 30, the company rating was maintained by Chardan Capital Markets. The rating was initiated by H.C. Wainwright on Monday, December 12 with “Buy”. The stock of Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) earned “Buy” rating by Cowen & Co on Wednesday, August 16. The firm earned “Hold” rating on Friday, August 11 by Chardan Capital Markets. As per Thursday, June 30, the company rating was maintained by Stifel Nicolaus. The firm earned “Buy” rating on Monday, February 5 by SunTrust. Stifel Nicolaus maintained the shares of DRNA in report on Monday, August 10 with “Buy” rating. Chardan Capital Markets maintained Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) on Monday, August 15 with “Neutral” rating. Stifel Nicolaus maintained it with “Buy” rating and $20 target in Wednesday, November 11 report.
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for rare, chronic liver, cardiovascular, and viral infectious diseases in the United States and internationally. The company has market cap of $659.98 million. The companyÂ’s preclinical stage development programs include DCR-PHXC for the treatment of primary hyperoxaluria type 1; DCR-PCSK9, which targets the PCSK9 gene in the treatment of statin-refractory patients with hypercholesterolemia; and DCR-HBV for the treatment of chronic hepatitis B virus infection, as well as other product candidates for use in the treatment of cardiovascular and chronic liver diseases. It currently has negative earnings. It has a research collaboration and license agreements with Kyowa Hakko Kirin Co., Ltd.; City of Hope, an academic research and medical center; and Plant Bioscience Limited.
Investors sentiment increased to 0.79 in Q3 2017. Its up 0.24, from 0.55 in 2017Q2. It is positive, as 9 investors sold Dicerna Pharmaceuticals, Inc. shares while 10 reduced holdings. 8 funds opened positions while 7 raised stakes. 10.37 million shares or 6.06% less from 11.04 million shares in 2017Q2 were reported. Ra Cap Lc has invested 1.26% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Ecor1 Capital Lc owns 957,992 shares for 0.73% of their portfolio. Geode Capital Management Lc holds 0% or 91,737 shares. Millennium Mgmt Lc reported 27,559 shares. Palo Alto Invsts Limited Liability Co, a California-based fund reported 500,913 shares. Moreover, Renaissance Llc has 0% invested in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Blackrock Inc holds 0% of its portfolio in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) for 113,396 shares. Birchview Cap Limited Partnership accumulated 45,000 shares. Deutsche National Bank & Trust Ag holds 0% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) or 51,681 shares. 17,650 are owned by Art Limited Liability Corporation. Jpmorgan Chase And Com owns 0% invested in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) for 1,600 shares. The North Carolina-based Bank Of America De has invested 0% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Dimensional Fund Advisors Limited Partnership has invested 0% in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA). Barclays Public Limited Liability holds 0% or 78 shares. Morgan Stanley owns 1,189 shares.
The post Swarthmore Group Has Decreased Thermo Fisher Scientific (TMO) Holding By $1.94 Million; Shorts at Dicerna Pharmaceuticals (DRNA) Lowered By 52.67% appeared first on Stock Market News | HillCountryTimes | Get it Today.
from
https://www.hillcountrytimes.com/2018/03/02/swarthmore-group-has-decreased-thermo-fisher-scientific-tmo-holding-by-1-94-million-shorts-at-dicerna-pharmaceuticals-drna-lowered-by-52-67/
No comments:
Post a Comment